Literature DB >> 8104410

Selective immunosuppression.

L Adorini1, J C Guéry, G Rodriguez-Tarduchy, S Trembleau.   

Abstract

Experimental models of autoimmune diseases have demonstrated that such disease can be prevented or treated by selectively interfering with activation of any of these cell types: antigen-presenting cells, autoreactive T cells and regulatory T cells. Luciano Adorini and colleagues discuss these approaches to selective immunosuppression and examine how similar strategies may become applicable to the treatment of human autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104410     DOI: 10.1016/0167-5699(93)90047-O

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


  8 in total

1.  Anti-proliferative effects induced by anti-CD4 human/murine chimeric antibody and murine anti-CD4 monoclonal antibody.

Authors:  G Shen; H Zhu; X Wang; Y Zhang; Z Zhu; S Wang
Journal:  J Tongji Med Univ       Date:  1999

2.  T cell receptor biases and clonal proliferations among lung transplant recipients with obliterative bronchiolitis.

Authors:  S R Duncan; V Valentine; M Roglic; D J Elias; K W Pekny; J Theodore; D H Kono; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

3.  Expression of anti-CD4 human/murine chimeric antibody and their killer tumor activity.

Authors:  G Shen; Z Zhu; H Zhu; J Shao; X Wang; W Xiong
Journal:  J Tongji Med Univ       Date:  1998

4.  3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts.

Authors: 
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

Review 5.  Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis?

Authors:  A D Dick
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

6.  Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease.

Authors:  P Middel; P Thelen; S Blaschke; F Polzien; K Reich; V Blaschke; A Wrede; K M Hummel; B Gunawan; H J Radzun
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

7.  Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Int J Exp Pathol       Date:  2004-12       Impact factor: 1.925

Review 8.  Immunomodulator therapy in inflammatory bowel disease.

Authors:  P M Choi; S R Targan
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.